T. Rowe Price Associates
BLU

T. Rowe Price Associates’s BELLUS Health Inc. BLU Stock Holding History

T. Rowe Price Associates’s Portfolio BLU Stock Details BLU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-992,997
Closed -$10.2M – 2639
2020
Q2 		$10.2M Buy
992,997
+272,563
+38% +$2.76M ﹤0.01% 1293
2020
Q1 		$7.19M Buy
+720,434
New +$6.42M ﹤0.01% 1283

Other funds holding BLU

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

T. Rowe Price Associates's BLU Position: Q3 2020 in Review

T. Rowe Price Associates sold out of BELLUS Health Inc. (BLU) in Q3 2020, closing a stake of 992,997 shares — an estimated $10.2M sold.

T. Rowe Price Associates first reported a position in BLU in Q1 2020 and held it in 2 quarters. The position peaked at $10.2M in Q2 2020. 50 funds tracked by Wall St. Rank hold BLU as of Q3 2020.

  • T. Rowe Price Associates reported no remaining BELLUS Health Inc. position as of Q3 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 992,997 BELLUS Health Inc. shares in Q3 2020, an estimated $10.2M.
  • T. Rowe Price Associates first reported a position in BELLUS Health Inc. in Q1 2020 and held it in 2 quarters.
  • T. Rowe Price Associates's BELLUS Health Inc. position peaked at $10.2M in Q2 2020.
  • 50 funds tracked by Wall St. Rank held BELLUS Health Inc. as of Q3 2020.

Based on T. Rowe Price Associates's 13F filing for Q3 2020, filed 16 Nov 2020.